Key Points
- Financial Lp Hrt sold 49,710 shares of Onconetix on April 21 at an average price of $0.69, cutting its holding by 59.63% to 33,649 shares valued at about $23,218.
- The same major shareholder carried out multiple mid‑April trades — buys on April 14, 15 and 17 and sales on April 16, 20 and 21 — showing concentrated, high turnover in the span of a week.
- Onconetix is a micro‑cap biotech (market cap about $477k) with a 12‑month range of $0.66–$74.29; institutional investors own 23.89% and Pacific Capital Wealth Advisors recently acquired 13,000 shares.
Onconetix, Inc. (NASDAQ:ONCO - Get Free Report) major shareholder Financial Lp Hrt sold 49,710 shares of the firm's stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $0.69, for a total transaction of $34,299.90. Following the transaction, the insider owned 33,649 shares in the company, valued at $23,217.81. This represents a 59.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The shares were sold at an average price of $0.73, for a total transaction of $39,322.91.
- On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The shares were sold at an average price of $0.75, for a total transaction of $70,846.50.
- On Friday, April 17th, Financial Lp Hrt purchased 34,636 shares of Onconetix stock. The shares were acquired at an average price of $0.73 per share, for a total transaction of $25,284.28.
- On Wednesday, April 15th, Financial Lp Hrt purchased 92,554 shares of Onconetix stock. The shares were acquired at an average price of $0.76 per share, for a total transaction of $70,341.04.
- On Tuesday, April 14th, Financial Lp Hrt bought 74,350 shares of Onconetix stock. The stock was bought at an average price of $0.77 per share, with a total value of $57,249.50.
Onconetix Stock Performance
ONCO opened at $0.73 on Thursday. The business has a 50 day moving average price of $2.45 and a 200 day moving average price of $8.45. Onconetix, Inc. has a twelve month low of $0.66 and a twelve month high of $74.29. The firm has a market cap of $477,371.20, a P/E ratio of 0.00 and a beta of 3.63.
Institutional Investors Weigh In On Onconetix
An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new position in Onconetix, Inc. (NASDAQ:ONCO - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,000 shares of the company's stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned about 0.84% of Onconetix as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 23.89% of the company's stock.
Onconetix Company Profile
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
